Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Forecast, Price & News $38.00 -0.63 (-1.63%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$37.98▼$39.0050-Day Range$34.05▼$40.7552-Week Range$32.96▼$55.80Volume621,057 shsAverage Volume621,555 shsMarket Capitalization$3.63 billionP/E RatioN/ADividend YieldN/APrice Target$56.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Cytokinetics MarketRank™ ForecastAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside48.1% Upside$56.29 Price TargetShort InterestBearish10.52% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.17Based on 4 Articles This WeekInsider TradingSelling Shares$4.06 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.46) to ($4.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector537th out of 985 stocksPharmaceutical Preparations Industry263rd out of 482 stocks 3.5 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $56.29, Cytokinetics has a forecasted upside of 48.1% from its current price of $38.00.Amount of Analyst CoverageCytokinetics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.52% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 9.4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 75.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.55. Previous Next 1.8 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cytokinetics this week, compared to 5 articles on an average week.Search Interest1 people have searched for CYTK on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,058,926.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.46) to ($4.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -8.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Cytokinetics (NASDAQ:CYTK) StockCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.Read More Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Stock News HeadlinesJune 2, 2023 | markets.businessinsider.comMizuho Securities Remains a Buy on Cytokinetics (CYTK)June 2, 2023 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Sells $470,875.00 in StockJune 6, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 27, 2023 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Upgraded at StockNews.comMay 26, 2023 | markets.businessinsider.comCytokinetics (CYTK) Gets a Buy from Mizuho SecuritiesMay 22, 2023 | markets.businessinsider.comWhat 20 Analyst Ratings Have To Say About CytokineticsMay 22, 2023 | msn.comHC Wainwright & Co. Reiterates Cytokinetics (CYTK) Buy RecommendationMay 22, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Cytokinetics (CYTK)June 6, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 22, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Cytokinetics (CYTK)May 21, 2023 | markets.businessinsider.comGoldman Sachs Remains a Buy on Cytokinetics (CYTK)May 20, 2023 | americanbankingnews.comStockNews.com Lowers Cytokinetics (NASDAQ:CYTK) to SellMay 19, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (CYTK) and Pfizer (PFE)May 19, 2023 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Downgraded by StockNews.comMay 18, 2023 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 17, 2023 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 12,500 Shares of StockMay 17, 2023 | americanbankingnews.comJohn T. Henderson Sells 4,166 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMay 16, 2023 | msn.comOppenheimer Reiterates Cytokinetics (CYTK) Outperform RecommendationMay 15, 2023 | finance.yahoo.comCytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 CongressMay 13, 2023 | americanbankingnews.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 1,787 Shares of StockMay 13, 2023 | americanbankingnews.comFY2023 EPS Estimates for Cytokinetics, Incorporated Lowered by Cantor Fitzgerald (NASDAQ:CYTK)May 11, 2023 | finance.yahoo.comCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586May 8, 2023 | finance.yahoo.comCytokinetics to Participate in the JMP Securities Life Sciences ConferenceMay 7, 2023 | finance.yahoo.comAnalysts' Revenue Estimates For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging HigherMay 7, 2023 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) PT Raised to $62.00May 4, 2023 | finance.yahoo.comCytokinetics (CYTK) Reports Q1 Loss, Tops Revenue EstimatesMay 4, 2023 | finance.yahoo.comCytokinetics Reports First Quarter 2023 Financial ResultsSee More Headlines CYTK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Company Calendar Last Earnings5/04/2023Today6/05/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees253Year Founded1997Price Target and Rating Average Stock Price Forecast$56.29 High Stock Price Forecast$80.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+48.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-388,950,000.00 Net Margins-439.05% Pretax Margin-439.35% Return on Equity-1,401.63% Return on Assets-43.52% Debt Debt-to-Equity RatioN/A Current Ratio9.05 Quick Ratio9.05 Sales & Book Value Annual Sales$94.59 million Price / Sales38.42 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-33.33Miscellaneous Outstanding Shares95,640,000Free Float92,007,000Market Cap$3.63 billion OptionableOptionable Beta0.80 Social Links Key ExecutivesRobert I. BlumPresident, Chief Executive Officer & DirectorEric TerhaerdtVice President-Development OperationsChing W. JawChief Financial Officer & Senior Vice PresidentFady Ibraham MalikExecutive Vice President-Research & DevelopmentAndy WolffSenior VP-Clinical Research & DevelopmentKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRTG TherapeuticsNASDAQ:TGTXUltragenyx PharmaceuticalNASDAQ:RAREBlueprint MedicinesNASDAQ:BPMCProthenaNASDAQ:PRTAView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Sold 37,236 shares on 6/1/2023Ownership: 0.038%Prelude Capital Management LLCBought 7,302 shares on 6/1/2023Ownership: 0.008%Robert I BlumSold 12,500 sharesTotal: $470,875.00 ($37.67/share)ProShare Advisors LLCSold 2,343 shares on 5/26/2023Ownership: 0.020%Legato Capital Management LLCSold 2,897 shares on 5/25/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions CYTK Stock - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price forecast for 2023? 12 Wall Street analysts have issued 12-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they predict the company's share price to reach $56.29 in the next year. This suggests a possible upside of 48.1% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2023? Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK stock has decreased by 17.1% and is now trading at $38.00. View the best growth stocks for 2023 here. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.14. The biopharmaceutical company earned $4.60 million during the quarter, compared to the consensus estimate of $2.50 million. Cytokinetics had a negative net margin of 439.05% and a negative trailing twelve-month return on equity of 1,401.63%. The firm's revenue for the quarter was up 300.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.02) earnings per share. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), Global X Guru Index ETF (GURU), American Century Mid Cap Growth Impact (MID), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC). What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). What is Cytokinetics' stock symbol? Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK." Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.29%), FMR LLC (13.45%), Wellington Management Group LLP (7.87%), State Street Corp (4.97%), American Century Companies Inc. (2.80%) and Pictet Asset Management SA (2.38%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytokinetics' stock price today? One share of CYTK stock can currently be purchased for approximately $38.00. How much money does Cytokinetics make? Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.63 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($4.58) on an earnings per share basis. How many employees does Cytokinetics have? The company employs 253 workers across the globe. How can I contact Cytokinetics? Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010. This page (NASDAQ:CYTK) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.